The Supreme Court will examine the case of Louisiana v. FDA, which raises significant questions about state regulations and abortion rights.
This case is part of a broader national conversation about mifepristone, a drug central to the ongoing debates over abortion access.
As legal battles continue to unfold, the implications of this case could have far-reaching effects on reproductive health policies across the country.